Table 1.
Laboratory and clinical characteristics of JAK2V617F positive PV patients from training cohort stratified by their variant allele frequency (VAF > / ≤ 50%).
| Laboratory and clinical characteristics | All patients (n = 576) | JAK2 V617F VAF ≤ 50% (n = 369; 64.1%) | JAK2 V617F VAF > 50 % (n = 207; 35.9%) | P values* |
|---|---|---|---|---|
| Age in year; median (range) | 61.4 (18–92) | 62.2 (18–92) | 59.4 (22–91) | 0.2 |
| Age ≥ 60 years; n (%) | 311 (54) | 210 (56.9) | 101 (48.8) | 0.06 |
| Sex females; n (%) | 241 (41.8) | 146 (39.6) | 95 (45.9) | 0.1 |
| Risk stratification; high risk n (%) | 348 (60.4) | 235 (63.7%) | 113 (54.6%) | 0.04 |
|
White blood cells x 109/L; median (range) N evaluable=530 |
9.8 (4.5–38.5) | 9.2 (4.5–38.5) | 12.1 (5.3–34.1) | <0.0001 |
|
White blood cells ≥ 11 ×109/L; n (%) N evaluable=530 |
201 (37.9) | 96 (27.3) | 105 (59) | <0.0001 |
|
Hemoglobin, g/dL; median (range) |
17.8 (15.8–24.5) | 17.6 (15.8–22.4) | 18.3 (15.9–24.5) | <0.0001 |
|
Hematocrit, % median (range) |
53.7 (47.9–75.9) | 52.7 (47.9–70) | 56.2 (48.5–75.9) | <0.0001 |
|
Platelets x 109/L; median (IQR) N evaluable =527 |
458 (154–1638) | 493 (154–1638) | 402 (155–1200) | <0.0001 |
|
Lactate dehydrogenase UI/L; median (range) N evaluable =428 |
278.5 (123–678) | 260 (123–675) | 352 (169–678) | <0.0001 |
|
Palpable splenomegaly; n (%) N evaluable =543 |
194 (35.7) | 92 (26.2) | 102 (53.1) | <0.0001 |
|
Constitutional symptoms; n (%) N evaluable =564 |
69 (12.2) | 38 (10.6) | 31 (15.2) | 0.1 |
|
Pruritus; n (%) N evaluable =565 |
223 (39.5) | 110 (30.5) | 113 (55.4) | <0.0001 |
| Arterial thrombosis before/at diagnosis; n (%) | 76 (13.2) | 51 (13.8) | 25 (12.1) | 0.5 |
| Arterial thrombosis at follow-up; n (%) | 49 (8.5) | 27 (7.3) | 22 (10.6) | 0.2 |
| Venous thrombosis before/at diagnosis; n (%) | 52 (9) | 28 (7.6) | 24 (11.6) | 0.1 |
| Venous thrombosis at follow-up; n (%) | 39 (6.8) | 9 (2.4) | 30 (14.5) | <0.0001 |
| Major bleeding before/at diagnosis; n (%) | 20 (3.5) | 14 (3.8) | 6 (2.9) | 0.6 |
| Major bleeding at follow-up; n (%) | 34 (5.9) | 17 (4.6) | 17 (8.2) | 0.08 |
|
Cardiovascular risk factors (at least one); n (%) N evaluable=476 |
295 (61) | 198 (65.3) | 97 (56.1) | 0.05 |
|
Active smocking; n (%) N evaluable=430 |
69 (16) | 57 (20.4) | 12 (7.9) | 0.0004 |
|
Diabetes; n (%) N evaluable=438 |
45 (10.3) | 27 (9.5) | 18 (11.6) | 0.5 |
|
Hyperlypidemia; n (%) N evaluable=439 |
70 (15.9) | 51 (18) | 19 (12.3) | 0.1 |
|
Hypertension; n (%) N evaluable=446 |
250 (56) | 161 (55.7) | 89 (56.7) | 0.8 |
|
Microcirculatory symptoms; n (%) N evaluable=545 |
170 (31.2) | 100 (28.7) | 70 (35.5) | 0.1 |
| MF progression; n (%) | 75 (13) | 16 (4.3) | 59 (28.5) | <0.0001 |
| AML progression: n (%) | 12 (2.1) | 4 (1.1) | 8 (3.9) | 0.03 |
| Death; n (%) | 96 (16.7) | 37 (10) | 59 (28) | <0.0001 |
| Median survival (years) | 21.7 | 23.9 | 19.6 | 0.5 |
* Significant p values highlighted in bold refer to comparison of VAF ≤ 50% and >50%.